Title from resource title page (viewed July 6, 2010).
INTERNAL BIBLIOGRAPHIES/INDEXES NOTE
Text of Note
Includes bibliographical references and index.
CONTENTS NOTE
Text of Note
Hepatitis A: epidemiology, transmission and natural history -- Hepatitis B: epidemiology, transmission and natural history -- Hepatitis C: epidemiology, transmission and natural history -- Hepatitis E: epidemiology, transmission and natural history -- HBV virology -- HCV virology -- Prophylaxis and vaccination of viral hepatitis -- Acute and chronic hepatitis B: diagnostic tests -- HBV treatment: standard of care -- HBV: resistance and implications for therapeutic strategies -- Hepatitis D: diagnostic procedures and therapy -- Acute and chronic hepatitis C: diagnostic tests -- Standard of care -- New agents for treatment -- Management of adverse drug reactions -- Extrahepatic manifestations of chronic hepatitis C -- Management of HBV/HIV coinfection -- Management of HCV/HIV coinfection -- Management of HBV/HCV coinfection -- Assessment of hepatic fibrosis in chronic viral hepatitis -- Diagnosis, prognosis & therapy -- Management of patients before and after liver transplantation -- Liver transplantation in hepatitis B and C and HIV coinfection -- Metabolic liver Diseases: haemochromatosis -- Metabolic liver Diseases: NAFLD & NASH -- Metabolic liver diseases: Wilson's Disease -- Autoimmune hepatitis, PSC and PBC: etiology, diagnosis, natural history and therapy -- Alcoholic hepatitis.
0
SUMMARY OR ABSTRACT
Text of Note
"Hepatology is a rapidly evolving medical field and will continue to be very exciting over the next few decades. The situation in viral hepatitis is similar to the HIV field 10-15 years ago when it started to become better understood and treatable. Today, hepatitis B viral replication can be suppressed by potent antiviral drugs but there are risks for the emergence of resistance. Strategies to enhance the eradication rates of HBV infection still need to be developed. On the other hand, hepatitis C virus infection can be eradicated by treatment with pegylated interferon plus ribavirin. However, particularly in those infected by HCV genotype 1 the sustained virologic response rates are still suboptimal. Many new antiviral drugs, especially protease and polymerase inhibitors, are currently in preclinical and clinical development, and the first data from larger clinical trials provide some optimism that the cure rates for patients with chronic hepatitis C will be enhanced with these new agents. In other areas of hepatology, e.g., for hereditary and metabol ic liver diseases, our knowledge is rapidly increasing and new therapeutic options are on the horizon."--Preface.